Statera BioPharma (Statera BioPharma) Additional Paid-In Capital : $133.53 Mil(As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Additional Paid-In Capital?

Statera BioPharma's quarterly additional paid-in capital declined from Mar. 2022 ($134.53 Mil) to Jun. 2022 ($133.47 Mil) but then increased from Jun. 2022 ($133.47 Mil) to Sep. 2022 ($133.53 Mil).

Statera BioPharma's annual additional paid-in capital increased from Dec. 2019 ($11.31 Mil) to Dec. 2020 ($23.95 Mil) and increased from Dec. 2020 ($23.95 Mil) to Dec. 2021 ($127.74 Mil).

Statera BioPharma Additional Paid-In Capital Historical Data

The historical data trend for Statera BioPharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Additional Paid-In Capital Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Additional Paid-In Capital

11.31

23.95

127.74

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Additional Paid-In Capital	Get a 7-Day Free Trial						126.22	127.74	134.53	133.47	133.53

Statera BioPharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Statera BioPharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (Statera BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Executives

Satishchandran Chandrasekhar	director	167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka	director, officer: Chief Operating Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit	officer: Chief Technology Officer	C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M.	officer: Chief Legal Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky	officer: Chief Medical Officer	2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam	officer: Chief Financial Officer	2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick	director	TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203